Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

Table 4 Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form Scores^a Over Time, Paliperidone Palmitate Group

	Week 5	Week 13	Week 25
All patients (observed cases)
Total score, n	67	59	45
Mean (SD)	49.6 (10.1)	48.0 (12.8)	49.6 (12.3)
Satisfaction with Medication, n	55	52	44
Mean (SD)	3.6 (0.9)	3.7 (1.1)	3.6 (1.2)
Overall Life Satisfaction, n	67	59	45
Mean (SD)	3.9 (1.0)	3.5 (1.2)	3.6 (1.2)
Patients who completed 25 weeks of treatment^b
Total score, n	45	45	45
Mean (SD)^a	49.2 (10.3)	47.8 (13.5)	49.6 (12.3)
Satisfaction with Medication, n	36	41	44
Mean (SD)	3.6 (0.9)	3.7 (1.2)	3.6 (1.1)
Overall Life Satisfaction, n	45	45	45
Mean (SD)	3.8 (1.0)	3.5 (1.3)	3.6 (1.2)

^aMaximum total score: 70
^bAll patients who had Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form data at weeks 5 and 25

ISSN: 1471-244X